Erik Cruz on how emerging pharma can improve product launches

Share on facebook
Share on twitter
Share on linkedin

An emerging biopharma company faces unique challenges at launch and, therefore, must work hard to build a comprehensive launch roadmap that is grounded in data, incorporates the right technology tools, and accounts for the inherent uncertainty associated with launching a first product. Erik Cruz writes in Pharmaceutical Executive about how commercial leaders of emerging companies can maximize results at launch.